SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

10 Nov 2022 Evaluate
Net sales declined -24.14%  to  Rs. 1121.72 million from Rs. 1478.58 millions.Net profit of the cmpany stood at Rs. 168.62 millions for the quarter ended September 2022 a decline of -71.04% from Rs. 582.21 millions  in the same quarter last year.Operating Profit reported a sharp decline to 541.47 millions from 971.04 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 1121.72 1478.58 -24.14 2135.27 2248.00 -5.01 5300.49 3912.45 35.48
Other Income 26.05 33.21 -21.56 49.62 52.60 -5.67 75.77 49.77 52.24
PBIDT 541.47 971.04 -44.24 877.50 1144.96 -23.36 2215.62 1781.51 24.37
Interest 237.55 168.87 40.67 243.36 178.61 36.25 41.98 40.80 2.89
PBDT 303.92 802.17 -62.11 634.14 966.35 -34.38 2173.64 1740.71 24.87
Depreciation 29.73 24.63 20.71 58.58 49.40 18.58 101.18 67.61 49.65
PBT 274.19 777.54 -64.74 575.56 916.95 -37.23 2072.46 1673.10 23.87
TAX 105.57 195.33 -45.95 154.44 257.35 -39.99 554.35 437.16 26.81
Deferred Tax 0.91 -1.90 -147.89 3.91 44.07 -91.13 32.46 6.94 367.72
PAT 168.62 582.21 -71.04 421.12 659.60 -36.16 1518.11 1235.94 22.83
Equity 160.97 146.37 9.97 160.97 146.37 9.97 160.97 146.37 9.97
PBIDTM(%) 48.27 65.67 -26.50 41.10 50.93 -19.31 41.80 45.53 -8.20

Supriya Lifescience Share Price

649.75 21.75 (3.46%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×